Barclays
BLTE icon

Barclays’s Belite Bio BLTE Stock Holding History

Barclays’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.11M Buy
30,074
+23,252
+341% +$3.77M ﹤0.01% 2022
2026
Q2 		$1.05M Hold
6,822
– – ﹤0.01% 2763
2026
Q1 		$1.09M Buy
6,822
+2,646
+63% +$445K ﹤0.01% 2709
2025
Q4 		$668K Buy
+4,176
New +$495K ﹤0.01% 3690
2022
Q4 		– Sell
-6,661
Closed -$223K – 5272
2022
Q3 		$223K Buy
+6,661
New +$230K ﹤0.01% 3136

Other funds holding BLTE

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
High Net Worth Advisory Group
High Net Worth Advisory Group Naples, Florida $476M AUM 15.5% 1-Year Est. Return
Dymon Asia Capital (Singapore)
Dymon Asia Capital (Singapore) Singapore $2.21B AUM 109.09% 1-Year Est. Return
SmartHarvest Portfolios
SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Vise Technologies
Vise Technologies New York $12B AUM 18.78% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
EverSource Wealth Advisors
EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return

Barclays's BLTE Position: Q3 2026 in Review

Barclays increased its Belite Bio (BLTE) stake by 341% in Q3 2026, buying an estimated $3.77M and bringing the position to 30,074 shares worth $5.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

Barclays first reported a position in BLTE in Q3 2022 and has held it in 5 quarters since. 18 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

  • Barclays held 30,074 shares of Belite Bio worth $5.11M as of Q3 2026.
  • Barclays bought 23,252 Belite Bio shares in Q3 2026, an estimated $3.77M.
  • Belite Bio made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2022 holding.
  • Barclays first reported a position in Belite Bio in Q3 2022 and has held it in 5 quarters since.
  • 18 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.